Drug intelligence / Profile preview

LM-316

Development stage: Preclinical
Lead developer: LaNova Medicines
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LM-316 is a **preclinical antibody-drug conjugate** being developed by **LaNova Medicines** for oncology indications including **non-small cell lung cancer, ovarian cancer, and triple-negative breast cancer**. Public pipeline sources identify it as an **ADC**, but the **molecular target, payload, linker, and detailed mechanism of action remain undisclosed** in the publicly accessible materials reviewed. Based on the sponsor pipeline, it appears to be an early-stage experimental antineoplastic biologic program in discovery/PCC or IND-enabling development rather than a clinically characterized asset.

Beyond the preview

Go deeper on LM-316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM-316.

Explore the full profile